Item 1.02 Termination of a Material Definitive Agreement

As previously disclosed, on September 15, 2020, resTORbio, Inc. (the predecessor of Adicet Bio, Inc., referred to herein as "resTORbio" or the "Company") entered into a Contingent Value Rights Agreement (the "Rights Agreement") with Computershare, Inc. and its wholly owned subsidiary, Computershare Trust Company, N.A. (jointly referred to herein as "Computershare"). The CVR Agreement entitled certain holders of resTORbio common stock to receive substantially all of the net proceeds from the commercialization, if any, received from a third party commercial partner of RTB101, a small molecule product candidate, previously developed by resTORbio, for a COVID-19 related indication.

Pursuant to Section 4.2(c) of the Rights Agreement, on October 27, 2021, the Company delivered written notice to Computershare to terminate its obligations under the Rights Agreement, effective as of October 27, 2021. The Company is not subject to any termination penalties related to the termination of the Rights Agreement.

A copy of the Rights Agreement was filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed on September 16, 2020. The description of the Rights Agreement contained in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the Rights Agreement filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed on September 16, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses